ArticleNature biomedical engineering2018

Efficacy and safety assessment of a TRAF6-targeted nanoimmunotherapy in atherosclerotic mice and non-human primates.

Marnix Lameijer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.